Evidence map›Paper›PMID 32980191›Full record

ArticleEuropean journal of cancer (Oxford, England : 1990)2020

Corrigendum to "Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicenter study of the Italian Melanoma Intergroup (IMI)" [Eur J Canc 137 (2020). Pages 30-39].

Mario Mandalà, Francesca Galli, Roberto Patuzzo, Andrea Maurichi, Simone Mocellin, Carlo R Rossi, Eliana Rulli, Maria Montesco, Pietro Quaglino, Virginia Caliendo and 13 more

Open access · bronzeAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of cancer (Oxford, England : 1990), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 10 institutions in 1 country.

Mario MandalàUnit of Medical Oncology, Papa Giovanni XXIII Hospital, Bergamo, Italy. Electronic address: mmandala@asst-pg23.it.
Francesca GalliMethodology for Clinical Research Laboratory, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Roberto PatuzzoMelanoma and Sarcoma Unit, Department of Surgery, IRCCS Fondazione Istituto Nazionale dei Tumori, Milan, Italy.
Andrea MaurichiMelanoma and Sarcoma Unit, Department of Surgery, IRCCS Fondazione Istituto Nazionale dei Tumori, Milan, Italy.
Simone MocellinUnit of Surgery, Veneto Institute of Oncology - IOV, Italy; University of Padua, Italy.
Carlo R RossiUnit of Surgery, Veneto Institute of Oncology - IOV, Italy; University of Padua, Italy.
Eliana RulliMethodology for Clinical Research Laboratory, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Maria MontescoPathological Anatomy and Histology, Veneto Institute of Oncology - IOV, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy.
Pietro QuaglinoDermatologic Clinic, Department of Medical Sciences, University of Turin Medical School, Turin, Italy.
Virginia CaliendoDepartment of Surgery, University of Turin Madical Scholl, Italy.
Vincenzo De GiorgiDepartment of Dermatology, University of Florence, Italy.
Barbara MerelliUnit of Medical Oncology, Papa Giovanni XXIII Hospital, Bergamo, Italy.
Corrado CaracòIstituto Nazionale Tumori IRCCS Fondazione 'G. Pascale', Naples, Italy.
Dario PiazzalungaUnit of Surgery, Papa Giovanni XXIII Hospital, Bergamo, Italy.
Alice LabiancaUnit of Medical Oncology, Papa Giovanni XXIII Hospital, Bergamo, Italy.
Simone RiberoPathological Anatomy and Histology, Veneto Institute of Oncology - IOV, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy.
Rebecca SenettaPathology Division, 'Città della Salute e della Scienza di Torino' University Hospital, Turin, Italy.
Andrea GianattiUnit of Pathology, Papa Giovanni XXIII Hospital, Bergamo, Italy.
Barbara ValeriDepartment of Pathology and Laboratory Medicine, IRCCS Fondazione Istituto Nazionale dei Tumori di Milano, Milan, Italy.
Daniela MassiHistopatology and Molecular Diagnostics, Careggi University Hospital, Florence, Italy.
Paolo A AsciertoUnit Melanoma, Cancer Immunotherapy and Innovative Therapies, Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale', Naples, Italy.
Mario SantinamiMelanoma and Sarcoma Unit, Department of Surgery, IRCCS Fondazione Istituto Nazionale dei Tumori, Milan, Italy.
Italian Melanoma Intergroup (IMI)
Ospedale Papa Giovanni XXIII · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITIstituto Oncologico Veneto · ITIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITMario Negri Institute for Pharmacological Research · ITUniversity of Turin · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITAzienda Ospedaliero-Universitaria Careggi · ITUniversity of Florence · ITUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID32980191
PMCPMC8445295
OpenAlexW3089214629

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.